1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

25 Nov 2020
Admin
News Article

Daiichi Sankyo Takes Oncology Shift Into Next Phase With New Global Business Unit

Daiichi Sankyo Is Taking Another Big Step In Its Transformation To Oncology Drugmaker. The Pharma Company Recently Laid Out Plans To Create An Integrated Oncology Business Unit, Tapping Current U.S. Business Chief Ken Keller To Take The Reins When It Opens Its Doors On April 1. The New Unit Consolidates All Of Daiichi&Rsquo;S U.S. And European Oncology Functions Across Global Marketing, Market Access And Pricing, And Medical Affairs, Along With Alliance Management, Which Covers Its Antibody-Drug Conjugate Partnership With Astrazeneca. Keller, Who Currently Serves As President And Ceo Of Daiichi Sankyo In The U.S., Will Become Head Of The Oncology Business Unit And Continue In His Daiichi Sankyo U.S. Role.&Ldquo;Our Plan Is To Become One Of The Fastest-Growing Oncology Companies Globally, As Measured By New Product Revenue,&Rdquo; Keller Said. &Ldquo;That&Rsquo;S What We&Rsquo;Re Driving Toward, And We&Rsquo;Ve Got Everything In Place Now. We&Rsquo;Ve Got The Development Organization, Manufacturing Organization And Now Will Have The Business Organization All Transformed And Focused On Oncologythe Move Is The Last Step In Daiichi&Rsquo;S Transformation From A Small-Molecule Metabolic And Cardiovascular Drugmaker To An Oncology Biologics Company. The Shift To Oncology Is Part Of The Company'S 2025 Business Plan, A Transition That Has Scored At Least One Major Approval So Far With More In The Wings.Daiichi And Astrazeneca&Rsquo;S Her2-Targeting Med Enhertu Launched In January&Mdash;Approved As A Third-Line Metastatic Breast Cancer Treatment&Mdash;And It Last Month Nabbed An Fda Priority Review For Her2-Positive, Metastatic Gastric Or Gastroesophageal Junction Cancer, With A Decision Date Set For Early Next Year.The Realignment With The New Unit Is Necessary Considering The Pace Of The Oncology Market. Daiichi Plans To Rack Up Four Or Five Indications Over The Next Few Years, Making Speed, Efficiency And Synergy More Important Than Ever, Keller Said.It Was Also Important To Daiichi To Make Sure The Business Unit Lined Up With Research From The Very Beginning Of Drug Development Because &Ldquo;In Oncology, It&Rsquo;S All About The Clinical Data, That&Rsquo;S What Moves The Market,&Rdquo; Keller Said.The Covid-19 Pandemic Forced Changes&Mdash;Enhertu Launched Shortly Before Shutdowns Began&Mdash;But Daiichi Learned Lessons It Can Take Into The Future, Including How To Gain Access To Oncologists And How To Create Effective Digital Communications And Virtual Educational Opportunities, He Said.&Ldquo;Even With Vaccines Coming, The World Won&Rsquo;T Go Back To The Way It Was,&Rdquo; Keller Said. &Ldquo;We Are Likely Never Going Back To Our Offices Five Days A Week In Basking Ridge. It&Rsquo;S Been A Forced Experiment, But It&Rsquo;S Been Working Fantastically

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!